LEEDS, England, December 13 /PRNewswire/ -- Teva UK Limited has announced plans to expand and strengthen its supply chain warehouse and logistic centre, and at the same time relocate its UK head office to new premises.
The company is planning to move its head office to Glasshoughton in West Yorkshire, at the junction of the M62 and A1 trunk roads, by the end of next year. The move will put the company's main logistics centre, as well as over 150 head office staff, in a brand-new expanded site that has a capacity no less than five times bigger than the firm's existing site near Leeds.
"This is a very exciting time at Teva UK Limited," said Managing Director John Beighton. "With the new respiratory, regulatory and Teva Europe Centre of Excellence at Harlow, plus investment in our plant at Eastbourne, we are consolidating our position as one of the UK's leading pharmaceutical companies. But more importantly, the new site will bring big improvements for our customers, as we finally have the space and the facilities to provide the best possible service."
The new site is about to start construction and will be equipped with the most modern equipment for storage and for picking of orders - an important consideration given that the company currently markets over 500 product lines and is believed to be the biggest single supplier of boxes of medicines to the NHS.
Notes for Editors:
Teva UK Limited is one of the UK's leading pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. With over 500 product lines, it has the widest range of any UK generic pharmaceutical company and has a number of respiratory products including the Qvar(R) (beclometasone dipropionate) CFC-free inhaler.
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra(R), Neurontin(R), Lotrel(R), and Famvir(R), the effects of competition on our innovative products, especially Copaxone(R) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Media enquiries: Paul Williams, Communications Manager, +44(0)113-201-3907 or +44(0)7798-582-889; or Philippa Ward, Communications & PR Officer, +44(0)113-201-3972 or +44(0)7921-495-697